University of New Mexi

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of New Mexi sits in the top decile of US sponsors by registered trial count (#286 of 15,742 sponsors by registered trial count).

76 total trials 23 currently recruiting 42 completed early-phase tilt top decile by trial count

University of New Mexi: 76 sponsored US clinical trials, 23 recruiting.

University of New Mexi sponsors 76 registered US clinical trials on ClinicalTrials.gov, 23 of them currently recruiting, and 42 completed. 3 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Pain, with 6 trials.

Top-decile sponsor footprint

University of New Mexi ranks in the top decile of sponsors by registered trial count (#286 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

42 of 42 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

76 total, page 2 of 2

COMPLETED

Tranexamic Acid and Blood Clots in Knee Surgery

NCT02867163

COMPLETED

Urease Breath Test for Rapid Characterization of Pneumonia

NCT03100760

COMPLETED NA

mTORC1 and Autophagy in Human Brown Adipocytes

NCT04206124

COMPLETED

Travelling for Rights

NCT03258463

COMPLETED NA

Music Therapy in Procedural Sedation in the Emergency Department

NCT02676206

COMPLETED Phase 2

Fluid Chloride and AKI in Cardiopulmonary Bypass

NCT02668952

COMPLETED Early Phase 1

Over-arousal as a Mechanism Between Alcohol and Intimate Partner Violence

NCT03037749

COMPLETED NA

Perineorrhaphy Outcomes Related to Body Imagery

NCT02548858

COMPLETED NA

Apneic Oxygenation During Airway Management in Pediatric Patients

NCT02437864

COMPLETED NA

Pilot Study of Combined Treatment for Veterans With Chronic Pain & Opiate Misuse

NCT02423772

COMPLETED NA

Family Listening Program: Multi-Tribal Implementation and Evaluation

NCT03142009

COMPLETED NA

Nitrous Oxide for Pain Management During In-office Transcervical Sterilization

NCT02312739

COMPLETED NA

Effectiveness of Peer-Delivered Trauma-Specific Treatment

NCT02081417

COMPLETED NA

Iwankapiya-Healing: Historical Trauma Practice and Group IPT for American Indians

NCT02124694

COMPLETED NA

Screening, Motivational Assessment, Referral, and Treatment in Emergency Departments

NCT01207791

COMPLETED Phase 1

Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia

NCT01169909

COMPLETED NA

Effect of Combined Exercise, Heat, and Quercetin Supplementation on Whole Body Stress Response

NCT01168739

COMPLETED NA

Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes

NCT00659165

COMPLETED NA

Acupuncture for Anxiety in Women With Breast Cancer: A Feasibility Study

NCT00322504

COMPLETED NA

A Comparison of Hydrochlorothiazide and Metolazone in Combination With Furosemide in Congestive Heart Failure Patients

NCT00690521

COMPLETED Phase 1

Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan

NCT00249977

COMPLETED Phase 2

INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.

NCT00276003

COMPLETED

Pre-Clinical Models in Gynecological Tumors A Tissue Repository

NCT00250783

COMPLETED Phase 4

Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in Women

NCT00375297

COMPLETED Phase 2

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

NCT00250796

COMPLETED Phase 1

A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors

NCT00251797

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 9
Phase 2 5
Phase 4 3

What is open in the University of New Mexi pipeline

23 recruiting of 76 indexed (30% open); 42 completed (55%).

Phase mix: 3 late (III/IV) vs 14 early (I/II) (early-phase heavy).

Top condition: Chronic Pain (6 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of New Mexi: open-pipeline peers nationwide

Peers matched on 76 registered trials and 30% open enrollment, not the therapeutic-area sidebar.

University of New Mexi sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 020406080100 10%15%20%25%30%35% Total trials Recruiting share University of New MexiIonis PharmaceuticalsMetroHealth Medical CenterTexas Tech University Health Sciences CenterUniversity of HawaiiTulane UniversityNew York UniversityAdverum BiotechnologiesCentre hospitalier de l'Université de Montréal (CHUM)
University of New Mexi sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of New Mexi sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 76 trials (± recruiting share)

Sponsors near 30% open enrollment (± trial volume)

What to do with this University of New Mexi page

76 registered trials is a research-attention snapshot, not an endorsement of University of New Mexi or any single study.

  • 23 of University of New Mexi's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Chronic Pain is the condition University of New Mexi studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Pain trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of New Mexi pipeline card: 76 registered trials from official public datasets.Report a data error.